Celldex Therapeutics
Hampton
About Celldex Therapeutics
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $1.8B
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2026)
- Ticker: nasdaq:CLDX
- Website: celldex.com
- Phone: (800) 736-3001
Industries & Categories
Biotechnology, Health Care, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/celldex-therapeutics-82281 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.